Thought Leadership

Rare cancers (RC) are a heterogeneous group of conditions that can be associated with psychological and physical impairments. The incidence of RC is less than six cases per 100,000 people/year1 but altogether, RC diseases account for approximately 24% of all cancer cases diagnosed, higher than any single common cancer2–4. Despite advances in treatments and more long-term survivors living with cancer as a chronic illness5 , five-year relative survival rates are still lower for patients with RCs than common cancers (47% vs. 65%)3

Recent regulatory developments and increasing domestic competition in China are now shaping development strategy for global companies

Investigate how incidence of rare cancers varies across the U.S, EU, Japan and China.

An overview of CAR-T trials by clinical phase of development for hematological and solid tumors

ADCs target tumor cells with toxic chemotherapy payloads. This interactive infographic detailing the extent of pivotal trial activity by developer, tumor type, molecular target, and payload chemotherapy class

Unique challenges face H&N cancer patients, which gives rise to important considerations driving treatments decisions

Trends in historical approvals and setbacks across different stages of disease in Esophageal, Pancreatic, Gastric, Hepatocellular, and Colorectal Cancers

Biomarker driven clinical trials have quickly built momentum in oncology. Explore and understand two decades of developmental trends across a variety of tumors.

While CDK4/6 inhibitors are at different stages of global adoption, they are indisputably the new standard of care bringing better outcomes to patients with HR+HER2- metastatic breast cancer.

Development of immuno-oncology drugs has risen dramatically. With 6 PD(L)1 agents now FDA approved, development now extends to multiple tumor types.

A more positive journey for patients with increased survival rates. View the some of the contributing factors over 2004 to 2014.

Use of PD(L)1 monoclonal antibodies (mABs) in NSCLC clinical trials has surged from 3% in 2012 to over 50% in 2017-19. View infographic for more details.

Many biotechs are looking for their first approval, including those with large clinical programs in the US and EU and ongoing Phase III trials.

For too long oncology patients have been treated with a one-size-fits-all treatment plan. The time has come for a more personalized approach.

Tumor-agnostic development strategies are gaining momentum as a way to treat solid and hematological tumors characterized by novel and existing biomarkers.

Data from the National Health & Wellness Survey suggests population aging and economic development influence the role of cancer caregivers and the degree of health, productivity, and financial impacts they report.

Could increased testing improve outcomes of more patients in rare cancer? And with HRR mutations occurring in multiple tumor types, are there more cancers these drugs can treat?

The diverse nature of NTRK fusions present challenges for identification and diagnosis given their rarity and heterogenous patient populations.

While CAR-T therapies are the dominant approach globally with development focused in the US and China, other therapy approaches are steadily rising.